Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest Content
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest Content
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 3, Issue 1
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
XML
Inflammatory bowel disease
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
Online download statistics by month:
Online download statistics by month: July 2017 to March 2024
Abstract
Full
Pdf
Jul 2017
41
41
13
Aug 2017
46
47
22
Sep 2017
31
31
11
Oct 2017
39
39
18
Nov 2017
50
50
17
Dec 2017
53
53
26
Jan 2018
40
40
14
Feb 2018
47
47
17
Mar 2018
78
72
24
Apr 2018
69
69
40
May 2018
68
69
23
Jun 2018
63
63
18
Jul 2018
120
118
21
Aug 2018
131
131
29
Sep 2018
126
125
25
Oct 2018
140
140
29
Nov 2018
133
133
17
Dec 2018
61
61
20
Jan 2019
64
62
21
Feb 2019
74
74
25
Mar 2019
81
81
32
Apr 2019
52
52
15
May 2019
77
76
27
Jun 2019
53
53
18
Jul 2019
64
65
17
Aug 2019
45
44
18
Sep 2019
40
39
11
Oct 2019
69
70
21
Nov 2019
28
28
19
Dec 2019
37
35
19
Jan 2020
54
53
19
Feb 2020
92
91
16
Mar 2020
60
60
33
Apr 2020
52
52
31
May 2020
58
59
19
Jun 2020
45
41
15
Jul 2020
59
51
26
Aug 2020
52
42
30
Sep 2020
55
48
20
Oct 2020
75
67
17
Nov 2020
69
59
28
Dec 2020
74
69
16
Jan 2021
81
73
24
Feb 2021
79
75
20
Mar 2021
108
96
22
Apr 2021
89
79
14
May 2021
74
71
19
Jun 2021
51
49
18
Jul 2021
60
53
16
Aug 2021
82
76
21
Sep 2021
84
83
17
Oct 2021
118
111
32
Nov 2021
102
96
32
Dec 2021
71
62
37
Jan 2022
102
96
29
Feb 2022
93
90
14
Mar 2022
104
103
20
Apr 2022
75
74
21
May 2022
60
60
18
Jun 2022
75
70
19
Jul 2022
117
108
15
Aug 2022
147
147
8
Sep 2022
144
134
15
Oct 2022
147
149
18
Nov 2022
152
153
23
Dec 2022
97
96
13
Jan 2023
220
213
22
Feb 2023
139
134
16
Mar 2023
108
95
19
Apr 2023
104
99
22
May 2023
133
131
11
Jun 2023
140
137
14
Jul 2023
95
99
15
Aug 2023
99
93
15
Sep 2023
90
89
16
Oct 2023
92
90
14
Nov 2023
117
110
18
Dec 2023
90
90
7
Jan 2024
26
26
8
Feb 2024
66
67
18
Mar 2024
151
149
17
Total
6747
6526
1614
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?